Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.47 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.47 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CPN1 | P15169 | 2/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL691260 | 1.00 | KDM4E (0.50) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL658030 | 1.00 | KDM4E (0.50) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL659836 | 0.92 | MAPT (0.38) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL690050 | 0.92 | MAPT (0.38) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL661356 | 0.92 | MAPT (0.38) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL2425678 | 0.89 | KDM4E (0.49) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL6586194 | 0.86 | SLC6A1 (0.49) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL363474 | 0.83 | GABRP (0.41) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL2461649 | 0.83 | CHRNB2 (0.36) | NOS2 | |
| SCHEMBL17732326 | 0.83 | KDM4E (0.36) | KDM4EMAPTKMT2AATMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555087-A1 | MONOCYCLIC OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109202-A1 | MONOCYCLIC OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-21 | — | — | WO | disclosed |
| US-8604205-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8604218-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2013-01-10 | — | — | US | disclosed |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2012-02-23 | — | — | US | disclosed |
| EP-2398320-A1 | AMIDOBIPIPERIDINECARBOXYLATE M1 ALLOSTERIC AGONISTS, ANALOGS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | Vanderbilt University (US) | 2011-12-28 | — | — | EP | disclosed |
| US-8071779-B2 | reduces intraocular pressure; primary open-angle glaucoma; effective to influence the actomyosin interactions by leading to cellular relaxation and alterations in cell-substratum adhesions | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| WO-2010096703-A1 | AMIDOBIPIPERIDINECARBOXYLATE M1 ALLOSTERIC AGONISTS, ANALOGS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | KDM4E 1941/4885MAPT 186/4885KMT2A 2573/4885 |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | KDM4E 1941/4885MAPT 186/4885KMT2A 2573/4885 |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | KDM4E 1941/4885MAPT 186/4885KMT2A 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.